Clinical Trial Search

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions

Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels — 5 percentage of participants

Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants

Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants

Primary: Rate of Rise of Serum PSA — 0.0825 Nanograms Per Milliliter

Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax

Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020

Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants

Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants

Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants

Primary: PSA Response — 0 participants

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Relapse-free Survival — 13; 10 months

Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants

Primary: Overall Survival — 91.6 weeks

Primary: Number of Patients With PSA Response, Defined as a 50% or Greater Decline in the Serum PSA Level — 0; 28; 4; 3 participants

Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true

Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data

Primary: Prostate Specific Antigen (PSA) Response — 2; 0 participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: PSA Response Rate With Bevacizumab Therapy in Androgen Independent Non-metastatic Prostate Cancer — 5 participants

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants